
Conference Coverage
about 2 hours ago
ALS Prevention, Gene Therapy, and Newborn Screening at MDA 2027about 22 hours ago
Levetiracetam Misses Primary Endpoint in Early Alzheimer Trialabout 23 hours ago
Infarct Size Alone Doesn't Predict Thrombectomy Outcomes, Registry ShowsLatest News

ALS Prevention, Gene Therapy, and Newborn Screening at MDA 2027

FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease

Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease

FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis

Perfuze Receives FDA Clearance for NeuroSheath 8F Long Sheath

Shorts










Continuing Medical Education
All News

A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.

A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.

Results from Eli Lilly's phase 2 PRESENCE-ALZ trial show the dopamine D1 receptor modulator missed its primary cognitive and functional goal in Alzheimer disease.

At an HCPLive and NeurologyLive Clinical Forum in Orlando, David Z. Rose, MD, of USF Morsani College of Medicine, discussed residual recurrence risk, dual antiplatelet therapy duration, and factor XIa inhibition in noncardioembolic stroke.

The senior director of research at the Muscular Dystrophy Association discussed what the newly approved once-weekly C5 inhibitor adds to generalized myasthenia gravis care.

Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.

The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.

Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.

In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS
A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.





























